The latest price target for NextCure (NASDAQ:NXTC) was reported by Needham on August 2, 2024. The analyst firm set a price target for $4.00 expecting NXTC to rise to within 12 months (a possible 189.86% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for NextCure (NASDAQ:NXTC) was provided by Needham, and NextCure reiterated their buy rating.

There is no last upgrade for NextCure

The last downgrade for NextCure Inc happened on November 4, 2022 when Ladenburg Thalmann changed their price target from N/A to N/A for NextCure Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NextCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NextCure was filed on August 2, 2024 so you should expect the next rating to be made available sometime around August 2, 2025.

While ratings are subjective and will change, the latest NextCure (NXTC) rating was a reiterated with a price target of $4.00 to $4.00. The current price NextCure (NXTC) is trading at is $1.38, which is out of the analyst’s predicted range.